Amarnath Natarajan

Leads a multidisciplinary team of investigators focused on developing target and mechanism specific modulators of disease relevant targets. Brings > 20 years of experience in all aspects of drug discovery. Advanced multiple compounds through preclinical studies that include ADMET and PD studies. Authored > 100 peer-reviewed scientific publications and continuously supported as PI on NIH grants for nearly 2-decades. Served on numerous review panels for various funding organizations, including as a permanent member on the NIH drug discovery and molecular pharmacology (DMP) study section.

BS: Madras Christian College Madras, India, 1994 (Chemistry)

MS: Indian Institute of Technology Madras, India, 1996 (Chemistry)

PhD: University of Vermont Burlington, VT, 2001 (Organic Chemistry)

04-01-2001 -04-30-2005 Postdoctoral Research Associate, Harvard Medical School, Boston, MA. "Developed small molecule translation initiation inhibitors for cancer therapy."

05-01-2005 -06-30-2009 Assistant Professor, University of Texas Medical Branch, Galveston, TX. "Established a research program focused on developing small molecule inhibitors of protein-protein interactions"

07-01-2009 -06-30-2014 Associate Professor, University of Nebraska Medical Center, Omaha, NE. "Expanded the research program to include targeting disease relevant proteins implicated in cancer"

07-01-2014 -07-31-2025 Professor, University of Nebraska Medical Center, Omaha, NE. "Led multidisciplinary drug discovery teams to advance compounds through preclinical development"

08-01-2017 -07-30-2024 Program Leader, Fred & Pamela Buffett Cancer Center, Omaha, NE. "Targets Modulators and Delivery"

07-01-2021 -07-31-2025 Ruth Branham Professor, University of Nebraska Medical Center, Omaha, NE. "Expanded the scope of the research program to include covalent modulators and heterobifunctional compounds (PROTACs & RIPTACs)"

06-01-2023 -05-30-2024 President, Faculty Senate, University of Nebraska Medical Center, Omaha, NE